Humanized Mouse Models for Immuno-Oncology Research

Humanized Mouse Models for Immuno-Oncology Research represent one of the most translationally relevant immuno-oncology tools

Home » Oncology CRO Services » Humanized Mouse Models for Immuno-Oncology Research

InnoSer’s Humanized Mouse Models for Immuno-Oncology Services

Humanized mouse models for immuno-oncology research are immunodeficient mice, with reconstituted human immune system (e.g., via PBMCs or CD34+ hematopoietic stem cells) co-engrafted with human tumors using either human cell lines or patient-derived tumor samples. Alternatively, transgenic knock-in humanized mouse models carrying human genes (such as human PD-1) are also available. This approach allows you to test your novel therapies with distinct patient tumor tissues and the human immune system of your choosing as the most accurate and specific representation of the patient tumor and immune system.  

Using patient-derived xenografts or cell line-derived xenografts, human tumor cells or tissues are implanted in mice that feature an intact humanized immune system, representing a powerful tool for immuno-oncology research. Compared to other models where immunodeficient mice are used, humanized mice represent more advanced models, with InnoSer’s expert recommendation to be used in the advanced stages of your preclinical research.

✓  Implantation of human tumors established from human cancer cell lines (cell line-derived xenograft mouse model) into humanized mice.

✓  Implantation of patient-derived tumors (patient-derived xenografts) into humanized mice. 

✓  Complementary PK/PD services. 

Humanized models

Developing new, safe, and efficacious anticancer therapies is an extremely intricate process. As a preclinical oncology contract research organization (CRO), InnoSer partners with you to help you navigate the complexities of this research area.  

Scientists at InnoSer collaborate with you to develop the most optimal study design to help answer your research questions in the most cost-effective way. With flexible and fast study start times you can perform your research at an accelerated pace. By outsourcing your preclinical oncology studies to InnoSer, you gain access to our in vitro and in vivo oncology drug development portfolio. 

Unlock the Right Tools for Your Research.

Explore and compare our oncology platforms to identify the perfect model for your study needs.

oncology leaflet download

InnoSer’s Humanized Mouse Models for Immuno-Oncology Readouts

InnoSer's Recommended Readouts


Test the efficacy of your treatments using CDX mouse models with the following readouts: 

 

  • Response to treatment (tumor growth kinetics, body weight, clinical signs, survival analyses) 
  • In vivo imaging (bioluminescence imaging, ultrasound)  
  • Isolation of tumors and other relevant organs for histopathology analyses 
  • Blood sampling for biomarker analyses (MSD) 

    The People Behind Your Research

    Céline Erens, PhD, Immunology Study Director

    An expert team led by our immuno-oncology study director, Céline Erens helps you choose the right tools and set up optimal study designs. Curating the preclinical testing of your lead compounds with a deep understanding of the field is your solution to accelerating your drug development.

    Yanick Fanton, PhD, Chief Scientific Officer

    As Chief Science Officer at InnoSer, Yanick is responsible for all customer studies at InnoSer and takes care of the scientific and technical coordination.

    Oncology Board Members

    Prof. Dr. Esther Wolfs

    A member of InnoSer’s Scientific Advisory Board, Dr. Wolfs is a leading researcher in stem cell therapy. Currently a professor at the University of Hasselt, Ester uses stem cells in anticancer therapy and as a model to study Charcot-Marie-Tooth disease type 1A.

    Marije Slingerland

    MD, PhD Marije Slingerland

    A member of InnoSer’s Scientific Advisory Board, Dr. Slingerland from Leiden University Medical Center focuses on clinical trials in gastrointestinal cancer and in head and neck cancer, particularly on intratumoral immune parameters.

    Stay Curious: More Articles to Explore

    Pancreatic Cancer PDX Models

    Pancreatic Cancer PDX Models

    Last month, November, represented Pancreatic Cancer Awareness Month; a time to focus on the challenges posed by one of the most aggressive and lethal cancer types. Pancreatic cancer accounts for approximately 3% of all diagnosed cancers in Europe, with pancreatic...

    RENCA Mouse Mouse Model of Renal Cancer

    RENCA Mouse Mouse Model of Renal Cancer

    Approximately 400,000 people are diagnosed with kidney cancer annually. Kidney tumors are classified into different subtypes based on the cell of origin. Over 85% of malignant renal cell tumors are RCC, with the other 15% being nephroblastic, mesenchymal and...

    Tumor microenvironment (TME) multiplex immunophenotyping analyses

    Tumor microenvironment (TME) multiplex immunophenotyping analyses

    The use of preclinical orthotopic tumors to better recapitulate the tumor microenvironment (TME) Complex interactions between the cellular and structural components of the tumor microenvironment (TME) composed of tumor cells, fibroblasts, endothelial cells, immune...

    AAALAC Accreditation

    InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.

    AAALAC logo

    Animal Welfare

    The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.